Onkure Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the 2025 Annual Meeting of Stockholders held by Onkure Therapeutics, Inc. on May 27, 2025. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Boulder, Colorado.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and does not contain financial performance data.
Material Changes and Voting Results
Stockholders voted on two proposals at the Annual Meeting:
- Proposal 1: Election of Directors
- Dr. Isaac Manke: Elected with 4,589,481 votes For, 882,303 Withheld, and 1,390,547 Broker Non-Votes.
- Dr. Nicholas Saccomano: Elected with 5,209,380 votes For, 262,404 Withheld, and 1,390,547 Broker Non-Votes.
- Both directors were elected to serve as Class I directors until the 2028 Annual Meeting.
- Proposal 2: Ratification of Independent Auditor
- Stockholders ratified the selection of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Votes: 6,750,408 For, 111,715 Against, 208 Abstentions, and 0 Broker Non-Votes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document serves solely to report the results of the stockholder vote.
Key Facts for Investor Verification
- Verify the tenure of newly elected directors Dr. Isaac Manke and Dr. Nicholas Saccomano (Class I, until 2028).
- Confirm the appointment of KPMG LLP as the independent auditor for the fiscal year ending December 31, 2025.
- Review the Proxy Statement filed on April 16, 2025, for detailed descriptions of the proposals and director biographies.